Market Cap | 51.47M | P/E | - | EPS this Y | -61.60% | Ern Qtrly Grth | - |
Income | -122.17M | Forward P/E | -0.81 | EPS next Y | 74.60% | 50D Avg Chg | -8.00% |
Sales | 18k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -12.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -87.00% |
Recommedations | 2.00 | Quick Ratio | 0.19 | Shares Outstanding | 23.70M | 52W Low Chg | 97.00% |
Insider Own | 3.63% | ROA | -86.80% | Shares Float | 11.49M | Beta | 0.94 |
Inst Own | 18.58% | ROE | - | Shares Shorted/Prior | 653.74K/473.14K | Price | 3.85 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 189,758 | Target Price | 27.80 |
Oper. Margin | -375,416.65% | Earnings Date | Nov 13 | Volume | 50,248 | Change | -2.28% |
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
HC Wainwright & Co. | Buy | Oct 2, 23 |
HC Wainwright & Co. | Buy | Aug 15, 23 |
HC Wainwright & Co. | Buy | Jul 27, 23 |
HC Wainwright & Co. | Buy | May 16, 23 |
HC Wainwright & Co. | Buy | Jan 10, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Sarna Surbhi | Director Director | Jul 05 | Sell | 0.61 | 7,517 | 4,585 | 148,774 | 07/05/22 |